TradeOrgs
  • Stocks
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← All stocks

🇺🇸ACHV

Achieve Life Sciences, Inc. - Common Shares

NASDAQ
$6.40
▲ $1.37 (+27.2%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 02 Jul 2026
H $7.11L $2.62+43.5%
$7.11$6.21$5.31$4.42$3.52$2.62$6.4
RSI (14)
Intraday · 15-minSell-20RSI 51DowntrendMACD Bullishfor day-trading context — not advice

Technical signal

Strong buy+60
RSI (14)66
oversold 30overbought 70
Trend
Uptrend
MACD
Bullish
Bollinger
Within bands
vs 20-day
above
vs 50-day
above
vs 200-day
above
Support
$4.82
Resistance
$7.11
  • Price is above its 50-day average (medium-term uptrend).
  • Price is above its 200-day average (long-term uptrend).

Signal backtest · 2025-09-29 → 2026-07-02

Strategy return
+112.8%
Buy & hold
+110.5%
Trades
3
Win rate
67%

$100,000.00 invested would be worth $212,808.77 (+112.8%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Achieve Life Sciences, Inc.· Biotechnology

source: yahoo

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

Sector
Healthcare
Industry
Biotechnology
Employees
28
Headquarters
Bothell, United States
www.achievelifesciences.com ↗

Fundamentals· Semiconductors

demo data

Live data was unavailable (the free feed can be rate-limited or blocked by region/host), so sample figures are shown. Set FINNHUB_API_KEY for a reliable fallback.

Market cap
$1.41T
P/E
14.8
P/B
3.3
EPS
$22.35
Div yield
1.4%
Profit margin
18.4%
ROE
22.5%
Debt / Equity
0.72
Beta
1.16
52-week range
$231.20 – $412.85
52-week low · $231.200% of rangehigh · $412.85

Recent news

News sentiment:— Neutral0↑ · 0↓ · 8–
  • Achieve Life Sciences Joins Russell 2000® Index— Neutral
    GlobeNewswire · 29 Jun 2026
  • Achieve Life Sciences Receives FDA Complete Response Letter for Cytisinicline— Neutral
    MT Newswires · 22 Jun 2026
  • Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA— Neutral
    GlobeNewswire · 22 Jun 2026
  • Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Fundamental data is informational only — not investment advice.

— Neutral
GlobeNewswire · 02 Jun 2026
  • Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment— Neutral
    GlobeNewswire · 19 May 2026
  • ACHV: CEO Enlists New Commercialization Team— Neutral
    Zacks Small Cap Research · 13 May 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.